US 11,807,882 B2
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
Edwin L. Madison, San Francisco, CA (US); Vanessa Soros, San Francisco, CA (US); and Mikhail Popkov, San Diego, CA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by VERTEX PHARMACEUTICALS INCORPORATED, Boston, MA (US)
Filed on Jul. 9, 2021, as Appl. No. 17/371,980.
Application 17/066,398 is a division of application No. 16/890,936, filed on Jun. 2, 2020, granted, now 10,954,501, issued on Mar. 23, 2021.
Application 17/066,398 is a division of application No. 17/371,980.
Application 17/371,980 is a division of application No. 16/890,936, filed on Jun. 2, 2020, granted, now 10,954,501, issued on Mar. 23, 2021.
Application 17/066,398 is a division of application No. 16/015,093, filed on Jun. 21, 2018, granted, now 10,781,435, issued on Sep. 22, 2020.
Application 16/890,936 is a division of application No. 16/015,093, filed on Jun. 21, 2018, granted, now 10,781,435, issued on Sep. 22, 2020.
Application 16/890,936 is a division of application No. 17/371,980.
Application 17/371,980 is a continuation of application No. 17/066,398, filed on Oct. 8, 2020, granted, now 11,401,513.
Application 17/371,980 is a continuation of application No. 16/015,093, filed on Jun. 21, 2018, granted, now 10,781,435, issued on Sep. 22, 2020.
Claims priority of provisional application 62/664,051, filed on Apr. 27, 2018.
Claims priority of provisional application 62/523,735, filed on Jun. 22, 2017.
Prior Publication US 2021/0355474 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/64 (2006.01); A61K 31/397 (2006.01); A61K 45/06 (2006.01); C07K 14/435 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/6424 (2013.01) [A61K 31/397 (2013.01); A61K 45/06 (2013.01); C07K 14/435 (2013.01); C12Y 304/21109 (2013.01); A61K 38/00 (2013.01)] 56 Claims
 
1. A modified membrane type serine protease (MTSP-1) polypeptide, comprising:
an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, wherein said amino acid sequence comprises, with reference to numbering in SEQ ID NO:1, the following modifications:
Q637H, I640S, D661T, F664S, Y666W, D705K, F706G, InsV, T707P, F708L, G759H, Q783L and Q802D (equivalent to Q38H, I41S, D60bT, F60eS, Y60gW, D96K, F97G, Ins97aV, T98P, F99L, G151H, Q175L, and Q192D, respectively, by chymotrypsin numbering); and wherein modifications comprise insertions, deletions and/or replacements in the unmodified MTSP-1 polypeptide.